ANXA6 and breast carcinoma: Moreover, cytotoxic drugs for breast cancer, such as taxanes and anthracyclines, could trigger the release of ANXA6-rich extracellular vesicles (ANXA6-EVs) from cancer cells, which promote tumor migration and invasion [27].